Numerous clinical trials spanning Early Phase 1 through Phase 4 evaluate Abemaciclib mesylate across diverse oncological indications, predominantly hormone receptor-positive, HER2-negative breast cancers, pediatric malignancies such as diffuse intrinsic pontine glioma and refractory solid tumors, hepatocellular carcinoma, and head and neck cancer. Sponsored by academic institutions including Rutgers University, Emory University, Moffitt Cancer Center, and Penn Medicine, these studies encompass active, recruiting, completed, and terminated statuses, featuring various Phase 1 combination and pediatric evaluations.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT07190443 | RECRUITING | Breast Cancer; Locoregional Recurrence; Abemaciclib; Endocrine Therapy |
Japanese Foundation for Cancer Research |
2025-02-07 | PHASE3 |
| NCT07340541 | RECRUITING | Breast Cancer; Metastatic Breast Cancer; Triple Negative Breast Cancer; Estrogen-receptor-positive Breast Cancer; Hormone Receptor Negative Breast Carcinoma |
UNC Lineberger Comprehensive Cancer Center |
2026-02-16 | PHASE2 |
| NCT01042379 | RECRUITING | Breast Neoplasms; Breast Cancer; Breast Tumors; Angiosarcoma; TNBC - Triple-Negative Breast Cancer; HER2-positive Breast Cancer; HER2-negative Breast Cancer; Hormone Receptor Positive Tumor; Hormone Receptor Negative Tumor; Early-stage Breast Cancer; Locally Advanced Breast Cancer |
QuantumLeap Healthcare Collaborative |
2010-03-01 | PHASE2 |
| NCT06169371 | RECRUITING | Breast Cancer |
University of Illinois at Chicago |
2023-12-28 | PHASE4 |
| NCT04584853 | ACTIVE_NOT_RECRUITING | Breast Cancer Female |
Institute of Cancer Research, United Kingdom |
2020-12-23 | PHASE3 |
| NCT05933395 | RECRUITING | Advanced Breast Cancer |
Dartmouth-Hitchcock Medical Center |
2024-09-23 | PHASE2 |
| NCT03424005 | RECRUITING | Metastatic Breast Cancer |
Hoffmann-La Roche |
2018-03-30 | PHASE1; PHASE2 |
| NCT05768139 | RECRUITING | Breast Cancer; Solid Tumors, Adult |
Eli Lilly and Company |
2023-04-17 | PHASE1; PHASE2 |
| NCT07553234 | NOT_YET_RECRUITING | Breast Cancer |
University of Chicago |
2026-12-27 | |
| NCT07191717 | RECRUITING | Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Invasive Breast Carcinoma; Localized Estrogen Receptor-Positive Breast Carcinoma; Localized Human Epidermal Growth Factor Receptor (HER2)-Negative Breast Carcinoma |
Jonsson Comprehensive Cancer Center |
2026-05-18 | PHASE2 |
| NCT05952557 | ACTIVE_NOT_RECRUITING | Breast Cancer, Early Breast Cancer |
AstraZeneca |
2023-10-05 | PHASE3 |
| NCT06380751 | RECRUITING | Advanced Breast Cancer |
AstraZeneca |
2024-08-01 | PHASE3 |
| NCT07490509 | NOT_YET_RECRUITING | Abemaciclib; Abemaciclib-related Diarrhea; Breast Cancer |
Poitiers University Hospital |
2026-09 | PHASE4 |
| NCT07605728 | RECRUITING | Breast Cancer; Chemotherapy-induced Diarrhea |
Leeuwenhoek Laboratories Co. Ltd. |
2026-05-15 | PHASE2 |
| NCT07521202 | NOT_YET_RECRUITING | HR+/HER2- Early Breast Cancer |
Institut fuer Frauengesundheit |
2026-06 | |
| NCT04802759 | RECRUITING | Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer |
Hoffmann-La Roche |
2021-06-22 | PHASE1; PHASE2 |
| NCT07174336 | RECRUITING | Breast Neoplasms; Neoplasm Metastasis |
Eli Lilly and Company |
2025-12-22 | PHASE3 |
| NCT07428018 | NOT_YET_RECRUITING | Breast Cancer; HER2 + Breast Cancer; HR Positive; Neoadjuvant Therapy |
Mario Negri Institute for Pharmacological Research |
2026-04-30 | PHASE2 |
| NCT07410559 | NOT_YET_RECRUITING | Breast Cancer |
Fudan University |
2026-07-01 | PHASE2 |
| NCT07492641 | RECRUITING | HR+/HER2- Breast Cancer |
BeOne Medicines |
2026-05-22 | PHASE3 |
| NCT05362760 | RECRUITING | Hormone Receptor-positive Metastatic Breast Cancer; HER2-negative Metastatic Breast Cancer |
Prof. Wolfgang Janni |
2022-04-27 | PHASE4 |
| NCT06760637 | ACTIVE_NOT_RECRUITING | Breast Cancer |
Pfizer |
2025-01-06 | PHASE3 |
| NCT04616183 | ACTIVE_NOT_RECRUITING | Metastatic Colon Adenocarcinoma; Metastatic Colorectal Carcinoma; Metastatic Rectal Adenocarcinoma; Recurrent Colorectal Carcinoma; Stage III Colon Cancer AJCC v8; Stage III Colorectal Cancer AJCC v8; Stage III Rectal Cancer AJCC v8; Stage IIIA Colon Cancer AJCC v8; Stage IIIA Colorectal Cancer AJCC v8; Stage IIIA Rectal Cancer AJCC v8; Stage IIIB Colon Cancer AJCC v8; Stage IIIB Colorectal Cancer AJCC v8; Stage IIIB Rectal Cancer AJCC v8; Stage IIIC Colon Cancer AJCC v8; Stage IIIC Colorectal Cancer AJCC v8; Stage IIIC Rectal Cancer AJCC v8; Stage IV Colon Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IV Rectal Cancer AJCC v8; Stage IVA Colon Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVA Rectal Cancer AJCC v8; Stage IVB Colon Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVB Rectal Cancer AJCC v8; Stage IVC Colon Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8; Stage IVC Rectal Cancer AJCC v8; Unresectable Colon Adenocarcinoma; Unresectable Colorectal Carcinoma; Unresectable Rectal Adenocarcinoma |
M.D. Anderson Cancer Center |
2020-12-02 | PHASE1; PHASE2 |
| NCT05524584 | RECRUITING | Breast Cancer; Metastatic Breast Cancer; Hormone Receptor-positive Breast Cancer; HER2-negative Breast Cancer |
University of California, Irvine |
2022-08-31 | PHASE2 |
| NCT04750928 | RECRUITING | Neurofibromatosis 1 |
National Cancer Institute (NCI) |
2021-11-29 | PHASE1; PHASE2 |
| NCT07292207 | NOT_YET_RECRUITING | ctDNA Monitoring; Breast Cancer |
Nagoya City University |
2026-01-10 | PHASE2 |
| NCT06678269 | RECRUITING | Metastatic Breast Cancer; Stage IV Breast Cancer; Breast Cancer; Breast Cancer Stage IV; Breast Cancer Metastatic; HER2-negative Breast Cancer; HER2 Negative Breast Carcinoma; Hormone-receptor-positive Breast Cancer |
Memorial Sloan Kettering Cancer Center |
2024-11-15 | PHASE1 |
| NCT07209449 | RECRUITING | Endometrial Cancer |
Memorial Sloan Kettering Cancer Center |
2025-10-01 | PHASE2 |
| NCT05940493 | RECRUITING | Meningioma |
Nader Sanai |
2025-03-24 | PHASE2 |
| NCT07100106 | RECRUITING | Breast Cancer |
Genentech, Inc. |
2025-10-07 | PHASE1; PHASE2 |
| NCT03675893 | RECRUITING | Endometrial Cancer |
Dana-Farber Cancer Institute |
2018-12-24 | PHASE2 |
| NCT07112053 | RECRUITING | Anatomic Stage IV Breast Cancer AJCC v8; Metastatic HER2-Negative Breast Carcinoma; Metastatic Hormone Receptor-Positive Breast Carcinoma |
University of Washington |
2025-11-17 | PHASE2 |
| NCT06062498 | RECRUITING | Estrogen-receptor-positive Breast Cancer; HER2/Neu-Negative Breast Cancer; Advanced Breast Cancerv; Metastatic Breast Cancer |
Northwestern University |
2023-09-29 | PHASE2 |
| NCT05708235 | RECRUITING | Breast Cancer |
MedSIR |
2024-04-01 | PHASE2 |
| NCT07706933 | NOT_YET_RECRUITING | Breast Cancer |
Henan Cancer Hospital |
2026-08-01 | |
| NCT04565054 | ACTIVE_NOT_RECRUITING | Breast Cancer Female |
Women's Cancer Study Group GmbH |
2020-09-02 | PHASE3 |
| NCT05891093 | RECRUITING | Breast Cancer |
Fudan University |
2023-06-01 | PHASE3 |
| NCT07002177 | RECRUITING | Metastatic Breast Cancer; Breast Cancer Stage I; Breast Cancer Stage II; Locally Advanced Breast Cancer (LABC); ER+ Breast Cancer |
Forward Pharmaceuticals Co., Ltd. |
2025-06-01 | PHASE1; PHASE2 |
| NCT04941274 | RECRUITING | Kaposi Sarcoma |
National Cancer Institute (NCI) |
2021-09-29 | PHASE1; PHASE2 |
| NCT04931342 | ACTIVE_NOT_RECRUITING | Ovarian Cancer |
Hoffmann-La Roche |
2021-10-07 | PHASE2 |
| NCT06813079 | RECRUITING | Pancreatic Ductal Carcinoma; Advanced Cancer; Epithelial Tumor |
University Health Network, Toronto |
2025-04-07 | PHASE2 |
| NCT02977780 | RECRUITING | Glioblastoma |
David Reardon, MD |
2017-02-09 | PHASE2 |
| NCT05573126 | RECRUITING | Hormone Receptor-positive Breast Cancer; Hormone Receptor Positive HER-2 Negative Breast Cancer; Metastatic Breast Cancer |
Ellipses Pharma |
2023-01-11 | PHASE1; PHASE2 |
| NCT05867251 | RECRUITING | Advanced Solid Tumor; HR+/HER2- Breast Cancer; HR+, HER2-, Advanced Breast Cancer; CCNE1 Amplification; Epithelial Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer; Endometrial Cancer; TNBC - Triple-Negative Breast Cancer |
Avenzo Therapeutics, Inc. |
2023-08-30 | PHASE1; PHASE2 |
| NCT05872204 | RECRUITING | Low Grade Serous Ovarian Carcinoma; Adult Type Granulosa Cell Tumor |
Universitaire Ziekenhuizen KU Leuven |
2023-11-30 | PHASE2 |
| NCT05608252 | RECRUITING | Breast Cancer; Hormone Receptor-positive Breast Cancer; Hormone Receptor Positive HER-2 Negative Breast Cancer |
Adrienne G. Waks |
2023-02-23 | PHASE1; PHASE2 |
| NCT02693535 | RECRUITING | Lymphoma, Non-Hodgkin; Multiple Myeloma; Advanced Solid Tumors |
American Society of Clinical Oncology |
2016-03-14 | PHASE2 |
| NCT07599137 | NOT_YET_RECRUITING | HR+/HER2- Breast Cancer |
Peking University Cancer Hospital & Institute |
2026-05-30 | PHASE4 |
| NCT04523857 | RECRUITING | Breast Cancer |
Abramson Cancer Center at Penn Medicine |
2021-11-01 | PHASE2 |
| NCT06365788 | RECRUITING | Triple Negative Breast Neoplasms |
Universitaire Ziekenhuizen KU Leuven |
2024-04-08 | PHASE2 |
| NCT04862663 | ACTIVE_NOT_RECRUITING | Locally Advanced (Inoperable) or Metastatic Breast Cancer |
AstraZeneca |
2021-05-10 | PHASE3 |
| NCT03531645 | ACTIVE_NOT_RECRUITING | Malignant Neoplasms of Female Genital Organs |
M.D. Anderson Cancer Center |
2019-08-13 | PHASE2 |
| NCT06366347 | RECRUITING | Endometrial Cancer; Recurrent Endometrial Cancer; TP53 |
Dana-Farber Cancer Institute |
2024-09-25 | PHASE2 |
| NCT02925234 | RECRUITING | Cancer; Tumors; Neoplasm; Neoplasia |
The Netherlands Cancer Institute |
2016-08 | PHASE2 |
| NCT06188520 | RECRUITING | ER+ HER2- Advanced Breast Cancer; High-grade Serous Ovarian Cancer (HGSOC) |
AstraZeneca |
2023-12-05 | PHASE1; PHASE2 |
| NCT04469764 | RECRUITING | Recurrent Endometrial Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma |
Jonsson Comprehensive Cancer Center |
2020-10-16 | PHASE2 |
| NCT03220646 | ACTIVE_NOT_RECRUITING | Brain Tumor |
Memorial Sloan Kettering Cancer Center |
2017-07-13 | PHASE2 |
| NCT05735080 | RECRUITING | Breast Cancer; Breast Cancer Metastatic; Hormone Receptor Positive Tumor; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; Ovarian Cancer; CCNE1 Amplification; Solid Tumor; Advanced Cancer; Metastatic Cancer |
Incyclix Bio |
2023-03-28 | PHASE1; PHASE2 |
| NCT02846987 | ACTIVE_NOT_RECRUITING | Sarcoma; Dedifferentiated Liposarcoma |
Memorial Sloan Kettering Cancer Center |
2016-07 | PHASE2 |
| NCT05372640 | RECRUITING | Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Breast Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic NUT Carcinoma; Unresectable Breast Carcinoma; Unresectable Malignant Solid Neoplasm; Unresectable NUT Carcinoma |
National Cancer Institute (NCI) |
2023-08-10 | PHASE1 |
| NCT04040205 | RECRUITING | Chondrosarcoma; Osteosarcoma; Soft Tissue Sarcoma |
Medical College of Wisconsin |
2019-10-07 | PHASE2 |
| NCT05774899 | RECRUITING | Adenoid Cystic Carcinoma; Metastatic Adenoid Cystic Carcinoma; Recurrent Adenoid Cystic Carcinoma |
Glenn J. Hanna |
2023-06-01 | PHASE1; PHASE2 |
| NCT05095207 | RECRUITING | Breast Cancer; Metastasis |
Icahn School of Medicine at Mount Sinai |
2021-09-20 | PHASE1; PHASE2 |
| NCT05113537 | RECRUITING | Castration-Resistant Prostate Carcinoma; Metastatic Prostate Adenocarcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8; Metastatic Castration-resistant Prostate Carcinoma; Metastatic Castration-resistant Prostate Cancer |
Vadim S Koshkin |
2022-07-08 | PHASE1; PHASE2 |
| NCT05999994 | RECRUITING | Neoplasms; Child; Adolescent |
Eli Lilly and Company |
2020-01-22 | PHASE2 |
| NCT07441369 | ENROLLING_BY_INVITATION | Liver Metastases From Colorectal Cancer (mCRC) |
Fudan University |
2026-07-30 | PHASE2 |
| NCT04614194 | RECRUITING | Breast Cancer |
University of Texas Southwestern Medical Center |
2021-04-15 | PHASE2 |
| NCT06654037 | RECRUITING | Metastatic Microsatellite Stable Colorectal Carcinoma; Refractory Microsatellite Stable Colorectal Carcinoma; Stage IV Colorectal Cancer AJCC v8 |
National Cancer Institute (NCI) |
2025-04-18 | PHASE1 |
| NCT05501704 | RECRUITING | Male Breast Cancer; Hormone Receptor-positive Breast Cancer; Hormone Receptor Negative Breast Carcinoma |
Jose Pablo Leone |
2023-10-11 | PHASE2 |
| NCT06409390 | RECRUITING | Metastatic Breast Cancer |
H. Lee Moffitt Cancer Center and Research Institute |
2024-08-14 | PHASE2 |
| NCT05696626 | RECRUITING | Metastatic Breast Cancer |
LeonaBio |
2023-10-31 | PHASE3 |
| NCT06810544 | RECRUITING | Non Small Cell Lung Cancer; Glioma Glioblastoma Multiforme; Glioma, Malignant; Solid Tumor; Non-Small Cell Adenocarcinoma; Lung Cancer; Brain Tumor |
Tango Therapeutics, Inc. |
2025-03-24 | PHASE1; PHASE2 |
| NCT05548127 | ACTIVE_NOT_RECRUITING | Breast Cancer |
Pfizer |
2023-02-23 | PHASE1; PHASE2 |
| NCT06594679 | RECRUITING | Ovarian Cancer |
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano |
2024-09-26 | PHASE1; PHASE2 |
| NCT06025747 | RECRUITING | Retroperitoneal Sarcoma; Liposarcoma; Dedifferentiated Liposarcoma |
University of Washington |
2025-03-19 | PHASE1 |
| NCT06179303 | RECRUITING | Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Locally Advanced Unresectable HER2-Negative Breast Carcinoma; Locally Advanced Unresectable Hormone Receptor-Positive Breast Carcinoma; Metastatic HER2-Negative Breast Carcinoma; Metastatic Hormone Receptor-Positive Breast Carcinoma |
University of Washington |
2024-07-22 | PHASE2 |
| NCT05691400 | WITHDRAWN | CYP3A4*22 |
University of Michigan Rogel Cancer Center |
2024-03 | PHASE4 |
| NCT06341621 | RECRUITING | Breast Cancer |
Fudan University |
2024-04-02 | PHASE3 |
| NCT06065748 | RECRUITING | Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer |
Hoffmann-La Roche |
2023-12-11 | PHASE3 |
| NCT06835972 | RECRUITING | Metastatic Renal Cell Carcinoma; Translocation Renal Cell Carcinoma |
Memorial Sloan Kettering Cancer Center |
2025-02-14 | PHASE1; PHASE2 |
| NCT06413706 | ACTIVE_NOT_RECRUITING | Glioma |
Eli Lilly and Company |
2024-10-25 | PHASE2 |
| NCT06498648 | RECRUITING | Advanced Dedifferentiated Liposarcoma; Advanced Leiomyosarcoma; Advanced Soft Tissue Sarcoma; Metastatic Dedifferentiated Liposarcoma; Metastatic Leiomyosarcoma; Metastatic Soft Tissue Sarcoma; Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8; Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 |
National Cancer Institute (NCI) |
2026-03-18 | PHASE1; PHASE2 |
| NCT06207734 | RECRUITING | Breast Cancer |
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest |
2024-01-17 | PHASE2 |
| NCT03310879 | RECRUITING | Cancer |
Dana-Farber Cancer Institute |
2017-11-21 | PHASE2 |
| NCT02523014 | RECRUITING | Intracranial Meningioma; Recurrent Meningioma; NF2 Gene Mutation |
Alliance for Clinical Trials in Oncology |
2015-09-28 | PHASE2 |
| NCT05714072 | RECRUITING | Myelofibrosis Due to and Following Polycythemia Vera |
Memorial Sloan Kettering Cancer Center |
2023-01-25 | PHASE1 |
| NCT04316169 | WITHDRAWN | Solid Tumor; Advanced Breast Cancer |
Medical College of Wisconsin |
2021-10-21 | PHASE1 |
| NCT05563220 | ACTIVE_NOT_RECRUITING | Breast Cancer; Metastatic Breast Cancer |
Stemline Therapeutics, Inc. |
2023-01-24 | PHASE1; PHASE2 |
| NCT05305924 | RECRUITING | ER-Positive Breast Cancer; HER2-negative Breast Cancer |
The Methodist Hospital Research Institute |
2021-02-25 | PHASE2 |
| NCT04393285 | ACTIVE_NOT_RECRUITING | Endometrial Cancer |
Gynecologic Oncology Group |
2020-10-10 | PHASE2 |
| NCT05307705 | RECRUITING | Breast Cancer |
Eli Lilly and Company |
2022-05-11 | PHASE1 |
| NCT05386108 | RECRUITING | Breast Neoplasms; Brain Neoplasms; Neoplasms by Site; Neoplasms; Breast Diseases; Central Nervous System Neoplasms; Brain Diseases; Central Nervous System Diseases |
Stemline Therapeutics, Inc. |
2022-08-31 | PHASE1; PHASE2 |
| NCT05159245 | RECRUITING | Advanced Cancer; Solid Tumor; Haematological Malignancy |
Helsinki University Central Hospital |
2021-12-10 | PHASE2 |
| NCT04923542 | RECRUITING | Brain Metastases; HR+ Metastatic Breast Cancer |
H. Lee Moffitt Cancer Center and Research Institute |
2021-11-30 | PHASE1; PHASE2 |
| NCT04633239 | RECRUITING | Recurrent Ovarian High Grade Serous Adenocarcinoma; Recurrent Platinum-Resistant Ovarian Carcinoma |
National Cancer Institute (NCI) |
2021-07-02 | PHASE1 |
| NCT04486352 | RECRUITING | Endometrial Cancer |
Alliance Foundation Trials, LLC. |
2021-10-20 | PHASE1; PHASE2 |
| NCT03994796 | ACTIVE_NOT_RECRUITING | CDK Gene Mutation; Metastatic Malignant Neoplasm in the Brain; Metastatic Malignant Solid Neoplasm; NTRK Family Gene Mutation; PI3K Gene Mutation; ROS1 Gene Mutation; KRAS G12C Mutation |
Alliance for Clinical Trials in Oncology |
2019-10-17 | PHASE2 |
| NCT06139107 | RECRUITING | Breast Cancer |
Mridula George, MD |
2024-08-22 | PHASE1 |
| NCT06959979 | RECRUITING | Medulloblastoma, Childhood |
Fondazione Policlinico Universitario Agostino Gemelli IRCCS |
2024-11-25 | EARLY_PHASE1 |
| NCT04305834 | RECRUITING | Anatomic Stage IV Breast Cancer AJCC v8; Hormone Receptor Positive Breast Carcinoma; Metastatic Breast Carcinoma; Prognostic Stage IV Breast Cancer AJCC v8 |
City of Hope Medical Center |
2020-03-25 | PHASE2 |
| NCT06570031 | COMPLETED | Hormone Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Metastatic Breast Cancer; Recurrent Breast Cancer |
Ono Pharmaceutical Co., Ltd. |
2021-11-09 | PHASE1 |
| NCT04010357 | COMPLETED | Small-cell Lung Cancer; Large Cell Neuroendocrine Carcinoma of the Lung; Extrapulmonary Small Cell Carcinoma |
Case Comprehensive Cancer Center |
2020-01-13 | PHASE2 |
| NCT06259929 | RECRUITING | Breast Cancer |
Fondazione Oncotech |
2025-01-27 | PHASE2 |
| NCT03643510 | COMPLETED | Adenocarcinoma of Endometrium |
Memorial Sloan Kettering Cancer Center |
2018-08-21 | PHASE2 |
| NCT06630325 | TERMINATED | Advanced Breast Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Ovarian Carcinoma; Advanced Pancreatic Carcinoma; Advanced Prostate Carcinoma; Advanced Sarcoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage III Prostate Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Stage IV Prostate Cancer AJCC v8 |
OHSU Knight Cancer Institute |
2025-06-24 | PHASE2 |
| NCT06585969 | WITHDRAWN | Metastatic Breast Cancer; ER-positive Breast Cancer; Luminal B; Her2 Enriched; Basal Like |
Danish Breast Cancer Cooperative Group |
2026-01-01 | PHASE3 |
| NCT06561022 | UNKNOWN | Breast Cancer |
Fudan University |
2024-08-21 | PHASE2 |
| NCT06810492 | NOT_YET_RECRUITING | Breast Cancer Stage III; Breast Cancer Stage II |
Hongmei Zheng, PhD |
2025-04-01 | |
| NCT04545710 | ACTIVE_NOT_RECRUITING | Lung Cancer |
University of California, San Diego |
2020-11-21 | PHASE2 |
| NCT04967521 | ACTIVE_NOT_RECRUITING | Advanced Dedifferentiated Liposarcoma |
Sarcoma Alliance for Research through Collaboration |
2021-11-11 | PHASE3 |
| NCT03891784 | ACTIVE_NOT_RECRUITING | Advanced Digestive System Neuroendocrine Neoplasm; Digestive System Neuroendocrine Tumor; Foregut Neuroendocrine Tumor; Hindgut Neuroendocrine Tumor; Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm; Metastatic Digestive System Neuroendocrine Neoplasm; Midgut Neuroendocrine Tumor; Pancreatic Neuroendocrine Tumor; Refractory Digestive System Neuroendocrine Neoplasm |
University of Washington |
2019-10-31 | PHASE2 |
| NCT05413304 | ACTIVE_NOT_RECRUITING | Glioma |
National Cancer Institute (NCI) |
2023-04-07 | PHASE1 |
| NCT07487129 | COMPLETED | Breast Cancer |
Beni-Suef University |
2024-08-25 | PHASE4 |
| NCT05766410 | RECRUITING | Breast Cancer; Hormone Receptor-positive Breast Cancer; Hormone Therapy |
National Taiwan University Hospital |
2022-09-16 | PHASE2 |
| NCT05617885 | COMPLETED | Metastatic Prostate Cancer; Non-metastatic Prostate Cancer; Prostate Cancer |
Praful Ravi, MB BCHir, MRCP |
2023-08-09 | PHASE1 |
| NCT04964934 | ACTIVE_NOT_RECRUITING | ER-Positive HER2-Negative Breast Cancer |
AstraZeneca |
2021-06-30 | PHASE3 |
| NCT04352777 | COMPLETED | Metastatic Breast Cancer; Locally Advanced Breast Cancer; Hormone Receptor Positive Tumor |
Duke University |
2020-09-14 | PHASE2 |
| NCT03969706 | ACTIVE_NOT_RECRUITING | Oligodendroglioma, Adult |
Stephen Bagley, MD, MSCE |
2019-05-15 | PHASE2 |
| NCT04158362 | ACTIVE_NOT_RECRUITING | Cancer Metastatic |
UNICANCER |
2020-06-11 | PHASE3 |
| NCT05759949 | COMPLETED | PIK3CA Mutation; Solid Tumor, Adult; HER2-negative Breast Cancer; Breast Cancer; Metastatic Breast Cancer; Advanced Breast Cancer; Unresectable Solid Tumor; Hormone Receptor Positive Tumor |
Relay Therapeutics, Inc. |
2023-03-29 | PHASE1 |
| NCT05464173 | UNKNOWN | Breast Cancer |
Biyun Wang, MD |
2022-07-01 | PHASE1; PHASE2 |
| NCT04432454 | COMPLETED | Metastatic Breast Cancer |
Sermonix Pharmaceuticals Inc. |
2020-09-29 | PHASE2 |
| NCT06001762 | ACTIVE_NOT_RECRUITING | Breast Cancer; Early-stage Breast Cancer; High Risk Breast Carcinoma |
Dana-Farber Cancer Institute |
2023-10-05 | PHASE2 |
| NCT05440786 | ACTIVE_NOT_RECRUITING | Sarcoma, Ewing; Neoplasm Metastasis |
Eli Lilly and Company |
2022-09-20 | PHASE2 |
| NCT04092673 | UNKNOWN | Solid Tumor, Adult |
Effector Therapeutics |
2019-10-25 | PHASE1; PHASE2 |
| NCT03732703 | COMPLETED | Relapsed Refractory Multiple Myeloma |
Multiple Myeloma Research Consortium |
2019-04-01 | PHASE1; PHASE2 |
| NCT04921904 | ACTIVE_NOT_RECRUITING | Metastatic Esophageal Adenocarcinoma; Metastatic Gastroesophageal Junction Adenocarcinoma |
Baylor Research Institute |
2021-06-11 | PHASE1; PHASE2 |
| NCT03979508 | TERMINATED | Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Breast Ductal Carcinoma In Situ; Breast Fibrocystic Change; Breast Lobular Carcinoma In Situ; Invasive Breast Carcinoma; Prognostic Stage I Breast Cancer AJCC v8; Prognostic Stage IA Breast Cancer AJCC v8; Prognostic Stage IB Breast Cancer AJCC v8; Prognostic Stage II Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Triple-Negative Breast Carcinoma |
Mayo Clinic |
2020-01-10 | PHASE2 |
| NCT04169074 | TERMINATED | HNSCC |
University of Arizona |
2021-07-07 | PHASE2 |
| NCT03284957 | TERMINATED | Breast Cancer |
Sanofi |
2017-09-20 | PHASE1; PHASE2 |
| NCT05189717 | UNKNOWN | Metastatic or Local Advanced Breast Cancer of Patients |
Shandong Suncadia Medicine Co., Ltd. |
2022-02-17 | PHASE1 |
| NCT06152471 | UNKNOWN | Early-stage Breast Cancer; Diarrhea; Adverse Drug Event |
Henrik Lindman |
2023-06-07 | PHASE3 |
| NCT03280563 | COMPLETED | Breast Neoplasms |
Hoffmann-La Roche |
2017-12-22 | PHASE1; PHASE2 |
| NCT03616587 | ACTIVE_NOT_RECRUITING | ER+ HER2- Advanced Breast Cancer |
AstraZeneca |
2018-10-11 | PHASE1 |
| NCT04791384 | TERMINATED | Breast Cancer |
Criterium, Inc. |
2022-04-21 | PHASE1; PHASE2 |
| NCT04227327 | TERMINATED | Advanced Breast Cancer |
University of Milano Bicocca |
2020-01-07 | PHASE2 |
| NCT04298983 | TERMINATED | Prostate Cancer |
University of Alabama at Birmingham |
2021-02-25 | PHASE2 |
| NCT04594005 | COMPLETED | Tumors |
Yonsei University |
2021-02-25 | PHASE1; PHASE2 |
| NCT03837821 | ACTIVE_NOT_RECRUITING | Bladder Cancer |
Weill Medical College of Cornell University |
2019-02-05 | EARLY_PHASE1 |
| NCT04603183 | COMPLETED | Breast Cancer Metastatic |
MedSIR |
2021-06-02 | PHASE2 |
| NCT02981940 | ACTIVE_NOT_RECRUITING | Glioblastoma |
Dana-Farber Cancer Institute |
2017-02-09 | PHASE2 |
| NCT04752332 | TERMINATED | Breast Neoplasms |
Eli Lilly and Company |
2021-05-10 | PHASE3 |
| NCT04975308 | ACTIVE_NOT_RECRUITING | Breast Neoplasms; Neoplasm Metastasis |
Eli Lilly and Company |
2021-10-04 | PHASE3 |
| NCT04751929 | COMPLETED | Prostate Cancer; Metastatic Castration-resistant Prostate Cancer |
Dana-Farber Cancer Institute |
2021-08-20 | PHASE2 |
| NCT06139107 | Recruiting | Breast Cancer |
Mridula George MD|Rutgers The State University of New Jersey |
2024-06-21 | Phase 1 |
| NCT06259929 | Not yet recruiting | Breast Cancer |
Fondazione Oncotech |
2024-04-01 | Phase 2 |
| NCT04238819 | COMPLETED | Relapsed Solid Tumor; Refractory Solid Tumor |
Eli Lilly and Company |
2020-11-09 | PHASE1; PHASE2 |
| NCT05999968 | TERMINATED | Prostatic Neoplasms |
Eli Lilly and Company |
2024-01-12 | PHASE1 |
| NCT05288166 | ACTIVE_NOT_RECRUITING | Prostatic Neoplasms; Neoplasm Metastasis; Urogenital Neoplasms; Physiological Effects of Drugs; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Androgens; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Abiraterone Acetate; Steroid Synthesis Inhibitors; Cytochrome P-450; Enzyme Inhibitors; Prednisone; Prednisolone; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6 |
Eli Lilly and Company |
2022-04-14 | PHASE3 |
| NCT04627064 | COMPLETED | Clear Cell Renal Cell Carcinoma |
Dana-Farber Cancer Institute |
2020-12-31 | PHASE1 |
| NCT05169567 | ACTIVE_NOT_RECRUITING | Breast Neoplasm; Neoplasm Metastasis |
Eli Lilly and Company |
2022-03-11 | PHASE3 |
| NCT03706365 | ACTIVE_NOT_RECRUITING | Prostate Cancer |
Eli Lilly and Company |
2018-11-26 | PHASE2; PHASE3 |
| NCT04118036 | WITHDRAWN | Glioblastoma |
Dana-Farber Cancer Institute |
2021-12-01 | PHASE2 |
| NCT05065411 | TERMINATED | Metastatic Breast Cancer |
Veru Inc. |
2022-04-11 | PHASE3 |
| NCT04074785 | TERMINATED | GBM; Glioblastoma; Brain Tumor; Brain Tumor, Recurrent |
University of Texas Southwestern Medical Center |
2019-12-13 | EARLY_PHASE1 |
| NCT04481113 | COMPLETED | Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage IA Breast Cancer AJCC v8; Anatomic Stage IB Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; HER2 Negative Breast Adenocarcinoma; Hormone Receptor Positive Breast Adenocarcinoma; Invasive Breast Carcinoma; Multifocal Breast Carcinoma; Prognostic Stage I Breast Cancer AJCC v8; Prognostic Stage IA Breast Cancer AJCC v8; Prognostic Stage IB Breast Cancer AJCC v8; Prognostic Stage II Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Unilateral Breast Carcinoma |
OHSU Knight Cancer Institute |
2021-06-07 | PHASE1 |
| NCT02644460 | COMPLETED | Diffuse Intrinsic Pontine Glioma; Brain Tumor, Recurrent; Solid Tumor, Recurrent; Neuroblastoma, Recurrent, Refractory; Ewing Sarcoma, Recurrent, Refractory; Rhabdomyosarcoma, Recurrent, Refractory; Osteosarcoma, Recurrent, Refractory; Rhabdoid Tumor, Recurrent, Refractory |
Emory University |
2016-02 | PHASE1 |
| NCT04256941 | TERMINATED | Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Breast Carcinoma; Prognostic Stage IV Breast Cancer AJCC v8 |
M.D. Anderson Cancer Center |
2019-05-31 | PHASE2 |
| NCT04003896 | TERMINATED | Biliary Tract Carcinoma |
Milton S. Hershey Medical Center |
2021-09-24 | PHASE2 |
| NCT04534283 | TERMINATED | Cancer; Cancer Metastatic; BRAF V600E; MEK1 Gene Mutation; MEK2 Gene Mutation; ERK Mutation; RAF1 Gene Mutation |
Anita Turk |
2020-10-05 | PHASE2 |
| NCT04391595 | COMPLETED | Glioblastoma; GBM; Glioma |
Nader Sanai |
2020-07-11 | EARLY_PHASE1 |
| NCT03939897 | ACTIVE_NOT_RECRUITING | Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Breast Carcinoma; Metastatic HER2-Negative Breast Carcinoma; Metastatic Hormone Receptor-Positive Breast Carcinoma; Recurrent Breast Carcinoma |
National Cancer Institute (NCI) |
2020-06-17 | PHASE1 |
| NCT04293393 | ACTIVE_NOT_RECRUITING | Early Breast Cancer |
Spanish Breast Cancer Research Group |
2020-10-02 | PHASE2 |
| NCT03099174 | COMPLETED | Neoplasms; Breast Neoplasms |
Boehringer Ingelheim |
2017-05-04 | PHASE1 |
| NCT04552769 | COMPLETED | Thyroid Cancer; Anaplastic Thyroid Cancer; Undifferentiated Thyroid Cancer |
Stanford University |
2020-09-10 | PHASE2 |
| NCT04049227 | COMPLETED | Endometrial Endometrioid Adenocarcinoma |
Northwestern University |
2019-08-12 | EARLY_PHASE1 |
| NCT03654833 | COMPLETED | Mesothelioma, Malignant |
University of Leicester |
2019-01-28 | PHASE2 |
| NCT04707196 | COMPLETED | Breast Neoplasms; Neoplasm Metastasis |
Eli Lilly and Company |
2021-02-22 | PHASE4 |
| NCT04801966 | TERMINATED | Cancer |
Peter MacCallum Cancer Centre, Australia |
2021-09-23 | |
| NCT03356223 | COMPLETED | Head and Neck Cancer; Advanced Cancer; Metastatic Cancer |
Centre Leon Berard |
2018-02-05 | PHASE2 |
| NCT04514159 | COMPLETED | Breast Cancer |
Zeno Alpha Inc. |
2020-11-12 | PHASE1 |
| NCT04272645 | WITHDRAWN | Prostate Cancer |
University of Michigan Rogel Cancer Center |
2020-10 | PHASE2 |
| NCT03781960 | TERMINATED | Hepatocellular Carcinoma |
Abramson Cancer Center at Penn Medicine |
2019-07-31 | PHASE2 |
| NCT04408924 | COMPLETED | Metastatic Castration-Resistant Prostate Cancer |
Eli Lilly and Company |
2021-01-20 | PHASE2 |
| NCT03988114 | WITHDRAWN | Metastatic Breast Cancer |
Eli Lilly and Company |
2019-09-16 | PHASE4 |
| NCT03905889 | TERMINATED | Renal Cell Carcinoma Metastatic |
Brown University |
2019-06-05 | PHASE1 |
| NCT04305236 | TERMINATED | Breast Neoplasm; Hormone Receptor Positive Breast Carcinoma |
University of California, Irvine |
2020-07-23 | PHASE2 |
| NCT04351230 | WITHDRAWN | Anatomic Stage IV Breast Cancer AJCC v8; HER2 Positive Breast Carcinoma; Metastatic Breast Carcinoma; Prognostic Stage IV Breast Cancer AJCC v8 |
Academic and Community Cancer Research United |
2020-11-11 | PHASE2 |
| NCT03339843 | COMPLETED | Esophageal Adenocarcinoma; Esophagus SCC; Cholangiocarcinoma; Urothelial/Bladder Cancer, Nos; Endometrial Cancer |
Jules Bordet Institute |
2018-12-19 | PHASE2 |
| NCT04585724 | WITHDRAWN | Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8; Metastatic Breast Carcinoma; Metastatic Malignant Neoplasm in the Brain; Prognostic Stage IV Breast Cancer AJCC v8 |
Emory University |
2020-06-12 | PHASE1 |
| NCT03130439 | TERMINATED | Breast Cancer |
Dana-Farber Cancer Institute |
2017-05-26 | PHASE2 |
| NCT02057133 | ACTIVE_NOT_RECRUITING | Breast Neoplasms |
Eli Lilly and Company |
2014-03-10 | PHASE1 |
| NCT04071262 | COMPLETED | Advanced Cancer |
Eli Lilly and Company |
2019-12-20 | PHASE1 |
| NCT02857270 | COMPLETED | Advanced Cancer; Metastatic Melanoma; Metastatic Non-small Cell Lung Cancer; Colorectal Cancer |
Eli Lilly and Company |
2016-09-29 | PHASE1 |
| NCT04088032 | WITHDRAWN | Breast Cancer Female; Locally Advanced Breast Cancer; Hormone Receptor Positive Malignant Neoplasm of Breast |
Alison Stopeck |
2019-10-01 | EARLY_PHASE1 |
| NCT03878524 | TERMINATED | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Anatomic Stage IV Breast Cancer AJCC v8; Anemia; Ann Arbor Stage III Hodgkin Lymphoma; Ann Arbor Stage III Non-Hodgkin Lymphoma; Ann Arbor Stage IV Hodgkin Lymphoma; Ann Arbor Stage IV Non-Hodgkin Lymphoma; Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Castration-Resistant Prostate Carcinoma; Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Hematopoietic and Lymphoid System Neoplasm; Locally Advanced Pancreatic Adenocarcinoma; Metastatic Breast Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Pancreatic Adenocarcinoma; Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Primary Myelofibrosis; Recurrent Acute Lymphoblastic Leukemia; Recurrent Acute Myeloid Leukemia; Recurrent Chronic Lymphocytic Leukemia; Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Recurrent Hematologic Malignancy; Recurrent Hodgkin Lymphoma; Recurrent Myelodysplastic Syndrome; Recurrent Myelodysplastic/Myeloproliferative Neoplasm; Recurrent Myeloproliferative Neoplasm; Recurrent Non-Hodgkin Lymphoma; Recurrent Plasma Cell Myeloma; Recurrent Small Lymphocytic Lymphoma; Refractory Acute Lymphoblastic Leukemia; Refractory Acute Myeloid Leukemia; Refractory Chronic Lymphocytic Leukemia; Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Refractory Chronic Myelomonocytic Leukemia; Refractory Hematologic Malignancy; Refractory Hodgkin Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Myelodysplastic Syndrome; Refractory Myelodysplastic/Myeloproliferative Neoplasm; Refractory Non-Hodgkin Lymphoma; Refractory Plasma Cell Myeloma; Refractory Primary Myelofibrosis; Refractory Small Lymphocytic Lymphoma; Stage II Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Stage IV Prostate Cancer AJCC v8; Unresectable Pancreatic Adenocarcinoma |
OHSU Knight Cancer Institute |
2020-04-01 | PHASE1 |
| NCT04165031 | TERMINATED | Advanced Solid Tumor; Non-Small Cell Lung Cancer; Colorectal Cancer |
Eli Lilly and Company |
2019-11-28 | PHASE1; PHASE2 |
| NCT03846583 | WITHDRAWN | Breast Cancer |
Dana-Farber Cancer Institute |
2020-06-28 | PHASE1 |
| NCT03655444 | TERMINATED | Head and Neck Squamous Cell Carcinoma |
Washington University School of Medicine |
2019-05-29 | PHASE1; PHASE2 |
| NCT04031885 | TERMINATED | Metastatic Breast Cancer |
Eli Lilly and Company |
2019-08-14 | PHASE4 |
| NCT04220892 | WITHDRAWN | High Grade Glioma |
Jose Carrillo |
2020-07-08 | EARLY_PHASE1 |
| NCT04188548 | ACTIVE_NOT_RECRUITING | Breast Cancer; Advanced Breast Cancer; Metastatic Breast Cancer; Endometrial Cancer |
Eli Lilly and Company |
2019-12-10 | PHASE1 |
| NCT02791334 | COMPLETED | Solid Tumor; Microsatellite Instability-High (MSI-H) Solid Tumors; Cutaneous Melanoma; Pancreatic Cancer; Breast Cancer (HR+HER2-) |
Eli Lilly and Company |
2016-06-29 | PHASE1 |
| NCT03938337 | TERMINATED | Head and Neck Cancer |
University of Alabama at Birmingham |
2019-10-08 | PHASE2 |
| NCT03155997 | ACTIVE_NOT_RECRUITING | Breast Cancer |
Eli Lilly and Company |
2017-07-12 | PHASE3 |
| NCT03292250 | COMPLETED | HNSCC; Head and Neck Neoplasms |
Seoul National University Hospital |
2017-09-10 | PHASE2 |
| NCT02779751 | ACTIVE_NOT_RECRUITING | Non Small Cell Lung Cancer; Breast Cancer |
Eli Lilly and Company |
2016-11-14 | PHASE1 |
| NCT03997448 | TERMINATED | Gastroesophageal Cancer; Adenocarcinoma |
Nataliya Uboha |
2019-08-26 | PHASE2 |
| NCT03356587 | UNKNOWN | HNSCC; Head and Neck Neoplasms |
Seoul National University Hospital |
2017-10-16 | PHASE2 |
| NCT03703466 | COMPLETED | Metastatic Breast Cancer |
Eli Lilly and Company |
2018-11-28 | PHASE2 |
| NCT02675231 | COMPLETED | Hormone Receptor Positive Breast Cancer; HER-2 Positive Breast Cancer |
Eli Lilly and Company |
2016-05-23 | PHASE2 |
| NCT01655225 | COMPLETED | Advanced Cancer; Metastatic Cancer; Non-Hodgkin's Lymphoma; Metastatic Breast Cancer; Malignant Mesothelioma; Non-small Cell Lung Cancer |
Eli Lilly and Company |
2012-07-31 | PHASE1 |
| NCT02763566 | ACTIVE_NOT_RECRUITING | Breast Cancer |
Eli Lilly and Company |
2016-12-05 | PHASE3 |
| NCT02919696 | COMPLETED | Advanced Cancer; Metastatic Cancer |
Eli Lilly and Company |
2017-08-07 | PHASE1 |
| NCT02308020 | COMPLETED | Breast Cancer; Non-small Cell Lung Cancer; Melanoma; Brain Metastases |
Eli Lilly and Company |
2015-04-20 | PHASE2 |
| NCT02745769 | COMPLETED | Advanced Cancer; Colorectal Cancer; Mantle Cell Lymphoma |
Eli Lilly and Company |
2016-10-21 | PHASE1 |
| NCT02784795 | TERMINATED | Solid Tumor; Breast Cancer; Colon Cancer; Cholangiocarcinoma; Soft Tissue Sarcoma |
Eli Lilly and Company |
2016-11-04 | PHASE1 |
| NCT02747004 | ACTIVE_NOT_RECRUITING | Metastatic Breast Cancer |
Eli Lilly and Company |
2016-09-14 | PHASE2 |
| NCT02079636 | COMPLETED | Carcinoma, Non-small Cell Lung |
Eli Lilly and Company |
2014-03-28 | PHASE1 |
| NCT02981342 | COMPLETED | Pancreatic Ductal Adenocarcinoma |
Eli Lilly and Company |
2017-01-12 | PHASE2 |
| NCT02688088 | COMPLETED | Neoplasm Metastasis |
Eli Lilly and Company |
2016-03-08 | PHASE1 |
| NCT02831530 | COMPLETED | Breast Cancer |
Gustave Roussy, Cancer Campus, Grand Paris |
2016-03-16 | PHASE2 |
| NCT02152631 | ACTIVE_NOT_RECRUITING | Non Small Cell Lung Cancer |
Eli Lilly and Company |
2014-10-03 | PHASE3 |
| NCT02411591 | COMPLETED | Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis |
Eli Lilly and Company |
2015-06-04 | PHASE1 |
| NCT02450539 | COMPLETED | Non-Small Cell Lung Cancer Stage IV |
Eli Lilly and Company |
2015-08-06 | PHASE2 |
| NCT02107703 | ACTIVE_NOT_RECRUITING | Breast Neoplasms |
Eli Lilly and Company |
2014-07-22 | PHASE3 |
| NCT02246621 | ACTIVE_NOT_RECRUITING | Breast Cancer |
Eli Lilly and Company |
2014-11-06 | PHASE3 |
| NCT02884089 | COMPLETED | Healthy |
Eli Lilly and Company |
2016-08 | PHASE1 |
| NCT02672423 | COMPLETED | Healthy |
Eli Lilly and Company |
2016-02 | PHASE1 |
| NCT02441946 | COMPLETED | Breast Cancer; Hormone Receptor Positive Tumor; Early-Stage Breast Carcinoma |
Eli Lilly and Company |
2015-08 | PHASE2 |
| NCT02677844 | COMPLETED | Healthy |
Eli Lilly and Company |
2016-02 | PHASE1 |
| NCT02102490 | COMPLETED | Metastatic Breast Cancer |
Eli Lilly and Company |
2014-06-10 | PHASE2 |
| NCT01739309 | COMPLETED | Mantle Cell Lymphoma |
Eli Lilly and Company |
2013-03-20 | PHASE2 |
| NCT02482935 | COMPLETED | Healthy |
Eli Lilly and Company |
2015-06 | PHASE1 |
| NCT02387814 | COMPLETED | Hepatic Insufficiency |
Eli Lilly and Company |
2015-03 | PHASE1 |
| NCT02117648 | COMPLETED | Neoplasm; Neoplasm Metastasis |
Eli Lilly and Company |
2014-04 | PHASE1 |
| NCT01394016 | COMPLETED | Advanced Cancer |
Eli Lilly and Company |
2009-12-07 | PHASE1 |
(data from https://clinicaltrials.gov, updated on 2025-09-29)
Check the
LY2835219 (Abemaciclib) Mesylate
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
- LY2835219 (Abemaciclib) Mesylate Mechanism of Action: CDK4/6 Inhibition in Breast Cancer Cell Research
- LY2835219 (Abemaciclib) Mesylate: Selectivity & Specificity
- LY2835219 (Abemaciclib) Mesylate Working Concentration | Cell Culture | Treatment
- LY2835219 (Abemaciclib) Mesylate Solubility in DMSO
- LY2835219 (Abemaciclib) Mesylate Stock Solution
- LY2835219 (Abemaciclib) Mesylate Storage
- LY2835219 (Abemaciclib) Mesylate Stability
- LY2835219 (Abemaciclib) Mesylate Combination Database
- LY2835219 (Abemaciclib) Mesylate Molecular Weight
- LY2835219 (Abemaciclib) Mesylate SMILES
- LY2835219 (Abemaciclib) Mesylate CAS Number
- LY2835219 (Abemaciclib) Mesylate Chemical Structure (2D and 3D)
- LY2835219 (Abemaciclib) Mesylate IC50 for Cell-based and Cell-free Assays
- LY2835219 (Abemaciclib) Mesylate Cayman (17740)? Try a better option.
- LY2835219 (Abemaciclib) Mesylate MedChemExpress (HY-16297)? Try a better option.
- LY2835219 (Abemaciclib) Mesylate Sigma (AMBH2D6FA628)? Try a better option.
- LY2835219 (Abemaciclib) Mesylate SDS｜MSDS
Note: Technical data last updated: Sep 1, 2026.